

**Category**

Best Incubator, Accelerator, Equity

**General Information****Program/Fund Name \***

Cube Labs

**Corporate Name \***

Cube Labs S.p.A.

**Date of Creation \***

2013-07-22

**Indications \***

Cube Labs is a healthcare venture builder that creates, develops, and scales early-stage life science companies by transforming high-potential scientific research into market-ready solutions. Through a platform-based model, Cube Labs integrates scientific, regulatory, and business expertise to build ventures from the ground up, prioritizing innovation with strong social impact, including rare diseases, public health challenges, and sustainable technologies. With a growing portfolio of startups, patents, and international partnerships, Cube Labs is committed to democratizing life sciences and delivering measurable improvements in global healthcare outcomes.

words remaining :

416

**Therapeutic Areas \***

Cube Labs' Areas of Interest include high-impact innovation across five core sectors: Pharmaceuticals, Biotech, MedTech, Nutraceuticals, and R&D Tech / AI. The focus spans therapeutic development, biological and digital health technologies, preventive health solutions, and artificial intelligence applied to the life sciences. Cube Labs selects ventures with strong scientific foundations and clear potential to improve patient outcomes, drive sustainability, and deliver measurable value across the global healthcare landscape.

words remaining :

432

\*Kindly clearly label your files with company name and asset name.

Attached Files:

- [Cube Labs Corporate Presentation\\_ENG.pdf](#)

**History of the development of the fund / Incubators**

(please be as specific as possible in your description; limit 500 words)

Cube Labs S.p.A. was founded with a clear ambition: to unlock the full potential of academic life sciences through a purpose-built venture builder platform designed for healthcare innovation. Rather than operating as a traditional incubator or investment fund, Cube Labs introduced a comprehensive venture-building model, tailored specifically for the biomedical and life sciences domains.

The company was co-founded by Filippo Surace, Renato Del Grosso, and Massimo Fiocchi, with the goal of transforming high-quality scientific discoveries into successful, scalable ventures. At its core, Cube Labs integrates all the key phases of innovation-technology scouting, due diligence, IP strategy, regulatory planning, market access, fundraising, and business development-into a single, coordinated framework.

A defining element of Cube Labs' model is its strong institutional partnership with INBB (Istituto Nazionale Biostrutture e Biosistemi), a research consortium under the Italian Ministry of University and Research. INBB links Cube Labs to a national network of over 24 leading universities and scientific centers, allowing for privileged access to frontier biomedical research and fostering a continuous pipeline of translational innovation.

By embedding its operations within the academic ecosystem, Cube Labs identifies and co-develops technologies that address unmet medical needs in fields such as biotech, medtech, nutraceuticals, and drug delivery. It provides researchers and clinicians with the operational and strategic infrastructure to move from proof-of-concept to go-to-market execution, helping bridge the classic "lab-to-market" gap in a pragmatic and repeatable manner.

From its earliest days, Cube Labs has been committed to a vision of accessible, globally relevant innovation. Its mission aligns with the United Nations Sustainable Development Goals, particularly those related to knowledge accessibility, health equity, and sustainable economic growth. Cube Labs promotes the democratization of life sciences, believing that impactful healthcare technologies should reach the widest possible populations.

At the international level, in alignment with its commitment to healthcare democratization, Cube Labs established a strategic partnership with Modi Global Enterprises in India. The Modi - Cube Labs alliance aims to introduce Cube Labs' proven, scalable venture builder model and technologies to the Indian market, for the purpose of transforming the life sciences landscape and enhancing much needed access to innovative solutions.

To date, Cube Labs has:

- Launched 17 life science ventures.
- Registered two commercial products.
- Successfully listed on the Milan Stock Exchange (Euro Growth Milan - Professional Segment) in March 2023, a major milestone for both the company and the venture-building model in Europe.

Cube Labs continues to serve as a unique integrator at the intersection of science, entrepreneurship, and impact. Through its ecosystem, it offers researchers, investors, and strategic partners a high-performance platform to create and scale next-generation healthcare solutions on a global scale.

words remaining :

63

### **History of the development of the fund / Incubators**

**(please be as specific as possible in your description; limit 500 words)**

Cube Labs is a healthcare venture builder with a distinct focus on bridging the critical gap between academic research and the global healthcare market, ensuring that high-potential scientific discoveries translate into real-world impact. The majority of Cube Labs' projects originate from within the academic ecosystem, where breakthrough innovations often lack the commercial and operational support needed to become viable businesses. To address this, Cube Labs has established strong institutional partnerships with Italy's foremost research networks and maintains privileged access to a vast pool of university-based technologies. Through this, Cube Labs scouts and develops early-stage ventures in therapeutics, diagnostics, nutraceuticals, and medical devices, providing researchers with a robust infrastructure that includes scientific and regulatory expertise, intellectual property strategy, business development, and commercialization pathways. This integrated approach enables Cube Labs not only to accelerate innovation but also to scale it efficiently through a modular and repeatable venture-building model.

At the heart of our work is the commitment to democratizing life sciences: we believe that innovation should serve the broadest population possible, across geographies and health systems. For this reason, we pursue ethical fundraising strategies, aligning with investors who share our long-term commitment to inclusive health equity, and we deliberately balance our market focus between mature and emerging economies, recognizing that the greatest impact of innovation often lies where healthcare access is most limited.

What distinguishes Cube Labs further is its position at the intersection of scientific excellence, entrepreneurial execution, and measurable social impact. We don't view these domains as separate ambitions but as interdependent pillars of value creation. Every venture we build is selected not only for its technical potential or commercial viability, but also for its capacity to address unmet medical needs, improve health outcomes, and contribute to a fairer, more resilient global healthcare ecosystem.

By setting measurable goals for accessibility, leveraging digital technologies, and optimizing cost structures, Cube Labs ensures that the solutions we build are not only cutting-edge, but also sustainable and scalable. In doing so, we provide a transformative path from the lab to society, building companies that improve outcomes, empower healthcare systems, and deliver meaningful advances for patients worldwide.

words remaining :

148

\*Kindly clearly label your files with company name and asset name.

### **How do you address your portfolio needs \***

**(please be as specific as possible in your description; 500 words)**

At Cube Labs, addressing the needs of our portfolio companies begins from the very first step: scouting. We adopt a dual strategy to identify high-potential opportunities: first, through direct sourcing of promising academic R&D projects, often stalled due to limited access to capital or commercialization pathways; second, via our Call for Impactful Ventures, an open initiative that attracts researchers and innovators with breakthrough ideas across therapeutics, diagnostics, and medical devices. Once a project is selected, we provide comprehensive, 360-degree support through a true venture builder model, ensuring that each startup receives operational, strategic, and financial backing from the earliest stages.

Unlike VCs that fund pre-existing startups or accelerators offering short-term mentorship, Cube Labs originates new ventures in-house, developing the business model internally and staying deeply involved throughout the company's evolution. We offer a structured environment that includes entrepreneurial support grounded in operational excellence, strategic guidance from a multidisciplinary team of industry experts, and access to financial resources through a patient capital approach, allowing for thoughtful, long-term value creation rather than rushed exits. This "platformized" model accelerates each venture's market validation, go-to-market strategy, and early commercial traction, while building a strong, scalable foundation.

A cornerstone of our model is the belief that scientists should be empowered to do what they do best: research and development. Rather than pushing researchers into unfamiliar entrepreneurial roles, we preserve their focus on scientific innovation while our internal team assumes responsibility for translating the technology into a viable business. This includes managing IP strategy, regulatory planning, fundraising, clinical pathways, and commercialization. By integrating scientific excellence with professionalized venture execution, Cube Labs enables its portfolio companies to develop impactful solutions that address pressing global health challenges and deliver measurable improvements in patient outcomes.

words remaining :

214

### **Impact / Metrics to measure Success \***

Our core objective is twofold: first, to ensure that high-potential technologies do not remain confined to academia but are actively propelled into the commercialization pipeline; and second, to accelerate the availability of transformative solutions that can improve global health outcomes. In just four years, Cube Labs has launched 17 startups, backed by a portfolio of 58 patents and 30 proprietary technologies, with two products already registered for the market.

These results are the product of a unique venture-building approach grounded in scientific rigor, operational excellence, and long-term vision. Our companies have secured prestigious national grants, and Cube Labs itself has garnered increasing national and international recognition. Most recently, we were awarded the "Champion of Scalable Market-Ready Healthcare Ventures Italy 2025" by CFI.co, and the Motore Italia 2025 "Innovation" Award by Milano Finanza - Gruppo Class Editori, in recognition of our pioneering role as Italy's leading listed venture builder. In March 2023, Cube Labs completed its IPO on the Milan Stock Exchange (EGM Pro Segment), where our stock has since risen by over 15%, making it the best-performing share in its segment. A recent valuation by Intermonte projects the stock could reach €3.25 by the end of 2025—an approximate 50% increase—and potentially grow up to

10x by 2030. Most notably, a June 2025 Venture Valuation report places the total value of Cube Labs' equity portfolio at €53.7 million, underscoring the tangible value created through our platform and its ventures.

Beyond financial and technological KPIs, we assess our impact through the lens of accessibility, equity, and sustainability, in full alignment with ESG principles. A key goal for Cube Labs is to expand our model through strategic partnerships that amplify our reach and systemic influence. In this context, our alliance with Modi Group in India represents a milestone in our international strategy: by adapting our venture builder framework to a fast-growing but under-resourced innovation ecosystem, we aim to foster scalable healthcare solutions where they are most needed. We continue to work with academic institutions, public research consortia, private investors, and industrial stakeholders, building a network that allows us to replicate and export our model globally. For Cube Labs, success means not just building companies, but building capacity-converting science into solutions, enabling access to innovation, and delivering meaningful, measurable improvements in patient outcomes around the world.

#### **Why your model is innovative, \and/or how it will improve the human condition \***

Cube Labs' model is innovative because it reimagines how life science ventures are created and scaled, offering a platform-based alternative to traditional venture capital and accelerators. Unlike VCs that invest in already-formed startups or accelerators that provide short-term mentorship and limited resources, Cube Labs functions as a venture builder: we internally originate, develop, and operate companies from day one. This model embeds our operational, regulatory, and strategic expertise directly into each startup from inception, providing a structured and repeatable path to success. Startups benefit from entrepreneurial support based on executional excellence, access to a multidisciplinary team of scientific and industry experts, and patient capital that allows them to mature with long-term goals in mind. Our platform creates economies of scale, accelerates timelines, and significantly reduces the risk of failure-positioning us not just as a funder, but as an infrastructure for continuous innovation in health.

What sets Cube Labs apart is not only the efficiency of our model, but its deliberate focus on global unmet needs. We prioritize opportunities often overlooked by conventional investment frameworks- for example, research into rare diseases, which traditional funds often consider commercially unviable, and technologies addressing major social and public health challenges, which may require longer development horizons. In addition, we actively support projects based on circular economy principles, fostering sustainability throughout scientific and industrial processes. This intentional alignment with ESG values ensures that our work drives both innovation and inclusive, responsible impact.

Cube Labs exists to bridge the persistent gap between high-potential research and real-world application. Across many regions of the world, scientific discovery still struggles to reach the market due to a lack of integrated commercialization expertise, fragmented stakeholder ecosystems, and underdeveloped support structures. Our model was built precisely to solve these problems, connecting science with entrepreneurial execution and capital in a seamless, end-to-end platform. We provide all the critical infrastructure required to move from lab to market, ensuring that promising discoveries do not remain shelved, but are instead transformed into ventures with the ability to scale and improve lives globally.

In doing so, Cube Labs is not only enabling science to move forward-it is ensuring that innovation is inclusive, accessible, and oriented toward human health and societal benefit. We believe that the true value of innovation is only realized when it reaches the people who need it most. That's why our model is designed to democratize access to life science entrepreneurship, bring vital technologies to market faster, and deliver measurable impact in health systems and communities around the world.

words remaining :

85

**Please provide appropriate references (PubMed, Abstract, Website) \***

Website: <https://cube-labs.com/>

References:

- a) CFI.co Award: <https://cfi.co/awards/finance/2025/cube-labs-champion-of-scalable-market-ready-healthcare-ventures-italy-2025/>
- b) Milan Stock Exchange: <https://www.borsaitaliana.it/borsa/azioni/elenco-completo-studi-societari.html?isin=IT0005532483&lang=en>
- c) Independent Researches: <https://www.borsaitaliana.it/borsa/azioni/elenco-completo-studi-societari.html?isin=IT0005532483&lang=en>